Skip to main content
$11.15 -$1.01 (-8.3%)

04:00 PM EDT on 10/22/21

Oyster Point Pharma (NASDAQ:OYST)

CAPS Rating: No stars

Current Price $11.15 Mkt Cap $290.1M
Open $11.94 P/E Ratio 0.00
Prev. Close $11.15 Div. (Yield) $0.00 (0.0%)
Daily Range $11.03 - $11.98 Volume 411,385
52-Wk Range $10.70 - $25.89 Avg. Daily Vol. 412,785

Caps

How do you think NASDAQ:OYST will perform against the market?

Add Stock to CAPS Watchlist

All Players

1 Outperform
0 Underperform
 

All-Star Players

0 Outperform
0 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:OYST Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Top Bull Pitch

There are no pitches that meet the Top Bull criteria. Explain

If this upsets you, start recommending pitches below!

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

NASDAQ:OYST VS S&P 500 (SPY)

NASDAQ:OYST Summary

Fools bullish on NASDAQ:OYST are also bullish on:

Recent Community Commentary

Read the most recent pitches from players about OYST.

Recs

0
Member Avatar odocoileus (56.70) Submitted: 8/1/2020 12:11:28 PM : Outperform Start Price: $23.65 NASDAQ:OYST Score: -90.64

OYST is wading into a competitive market against some big players. That always gives me pause, as I've been burned in this situation before. However, they only need $100-200M in sales to support their current market cap. In a 2.5B North American market and a 4.5B worldwide market for dry eye disease, there's probably room to run. Especially since they have a unique delivery method. It remains to be seen whether folks would rather inhale a drug than put drops in their eyes. The long process of manufacturing, marketing, and gaining insurance coverage is a long one, and I don't know how effective management will be in this arena. But they have passed PIII trials with flying colors, and we should see a bump on FDA submission, approval, and various announcements their PR machine should pump out as they progress through marketing. The real meat will be in sales, which should start mid 2021, so we won't know how that's going until the end of 2021 or into 2022. One could wait to see how sales develop, but it's rare to find a company that has passed PIII trials in a significant market with a low market cap.

Leaderboard

Find the members with the highest scoring picks in OYST.

Score Leader

guillu

guillu (64.86) Score: +42.57

The Score Leader is the player with the highest score across all their picks in OYST.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
odocoileus 56.70 8/3/2020 Outperform 5Y $23.65 -52.62% +38.02% -90.64 1 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for OYST.